Let’s Beat Bone Cancer Together
Osteosarcoma is the leading childhood bone cancer, but treatments haven’t advanced for 40 years. You can help change that. Start your own #SarcomaAwarenessMonth fundraiser or give today to fund a breakthrough.
Start a Facebook Fundraiser
For #SarcomaAwarenessMonth, encourage your friends to give toward osteosarcoma science. It only takes a few clicks to set up your own Facebook fundraiser, and it makes a big difference. In 2023, you helped raise over $18,000 for the Osteosarcoma Institute (OSI) on Facebook alone.
More Ways to Help
Sign Up for the Newsletter
Share Your Osteosarcoma Story
Make a Donation to Find a Cure
Report a Gift in Your Will
A foundational grant covers the OSI’s administrative expenses, so 100% of your tax-deductible donation goes directly to osteosarcoma research. Your support enables the Osteosarcoma Institute to continue our mission of identifying and funding the most promising and breakthrough osteosarcoma clinical trials and science.
You Are Making an Impact
The Osteosarcoma Institute has committed $6.8 million to osteosarcoma research since our inception. See how our experts and grant recipients are pushing the field forward.
OSI-Backed Research Explores Combo Immunotherapy
Osteosarcoma researcher Jason T. Yustein, MD, PhD, seeks to better understand the disease by testing various combinations of drugs to treat it.
Sequencing Osteosarcoma’s Chromosomal Complexity
Award-winning researcher Dr. Cortés-Ciriano explains how his work seeks to better understand osteosarcoma’s genomic instability to uncover novel treatments for the most aggressive types of the disease.
Overcoming the 4 Biggest Challenges in Drug Development for Rare Diseases
Fernanda Arnaldez, MD, explains that small sample sets, disease complexity, and limited funding pose challenges in rare disease drug development, but the field is rapidly evolving, making her optimistic about the future.
Osteosarcoma Statistics
Who We Work With
At the Osteosarcoma Institute, we care about progress — not who gets the credit. We collaborate with organizations throughout the cancer and sarcoma spaces.